Biocon Limited — PPTs, 08-05-2026: Investor Presentation

Biocon wrapped up FY26 with a strong performance, shifting from an investment phase to execution and value creation. Q4 revenue jumped 10% YoY (adjusted) to 4,517 Cr, with full-year revenue at 17,270 Cr, up 14% (adjusted). EBITDA also saw robust growth, rising 29% YoY (adjusted) in Q4 to 1,073 Cr and 25% (adjusted) for FY26 to 3,798 Cr. Net profit before exceptional items saw significant YoY growth.

Biosimilars led the charge, with Q4 revenue up 12% to 2,756 Cr, primarily driven by North America, and full-year revenue reaching 10,431 Cr (+16%). Generics revenue grew 13% (adjusted) in Q4 to 847 Cr, fueled by new gLiraglutide launches in Europe. CRDMO revenue saw modest 2% Q4 growth to 1,037 Cr.

Strategic focus includes leveraging a unified global biopharma platform post-integration and optimizing new capacity, shifting towards better utilization and margins. Recent highlights include expanded biosimilar approvals, new gLiraglutide approvals across key markets, and CRDMO extending its BMS partnership and commissioning new ADC capabilities. Management anticipates FY27 will focus on execution, scaling new biosimilar launches, improving generic profitability as utilization stabilizes, and progressive margin improvement for sustainable value creation.